Key Highlights
BUHLMANN Diagnostics Corp proudly participated in the 37th Annual Meeting of the Association of Medical Laboratory Immunologists (AMLI) from August 16-19, 2024, in Nashville, Tennessee. This event was a significant platform for showcasing our latest advancements and contributions to medical laboratory immunology.
AMLI 2024 Assays Offerings
Our booth showcased a comprehensive immunology assay product line at AMLI 2024.
Product Showcased:
- Anti-MAG Autoantibodies ELISA: The most sensitive and specific assay on the market for the quantitative determination of human IgM-auto-antibodies directed against Myelin Associated Glycoprotein (MAG) in serum. (US: Research Use Only. Not for use in diagnostic procedures)
- Flow CAST® (Basophil Activation Assay): A robust assay that offers an in-vitro ‘Allergy in a Vial’ for determining basophil activation in whole blood samples by flow cytometry. Utilizing CCR3 for basophil detection and CD63 for activation, it provides the most standardized and proven Basophil Activation Test (BAT) available. (US: Research Use Only. Not for use in diagnostic procedures)
Our Poster Presentation:
Analytical Validation and Stability Studies for Basophil Activation Test to Meet IVDR Certification At AMLI 2024, BUHLMANN Diagnostics Corp presented an insightful poster on the critical topic of market authorization for In Vitro Diagnostic (IVD) products. Key highlights from our poster included:
- Regulatory Challenges: Emphasizing the stringent requirements from regulatory bodies like the European Union, particularly the new regulation (EU) 2017/746 IVDR.
- Development and Validation: Highlighting the necessity of managing extensive development and validation studies to meet these regulatory standards.
- Documentation and Monitoring: Underlining the importance of providing comprehensive documentation and monitoring post-market performance data throughout the product life cycle.
For more details, you can view our poster HERE.
Looking Ahead:
AMLI 2024 was a remarkable event for BUHLMANN Diagnostics Corp, allowing us to highlight our innovative solutions. It also allowed us to connect with leading professionals in the field, fostering valuable collaborations and discussions. We look forward to continuing our contributions to the field of medical laboratory immunology and building strong relationships within the scientific community.
We appreciate everyone who stopped by our booth and engaged with our poster presentation. Your interest and support mean a lot to us. We look forward to reconnecting at AMLI 2025!
